GLP-1 Drug Discovery Success Transformed Pharmaceutical R&D
From gut hormones to global therapeutics, GLP-1 drug discovery transformed obesity treatment through peptide engineering and incretin biology translation.
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
From gut hormones to global therapeutics, GLP-1 drug discovery transformed obesity treatment through peptide engineering and incretin biology translation.
Generative AI is transforming clinical trials, but a failure to distinguish between pseudonymised and anonymised data is creating costly regulatory gaps.
The FDA PreCheck Pilot Program aims to strengthen U.S. domestic drug manufacturing through regulatory engagement, manufacturing readiness, and advanced production.
AI in neuroscience is driving big pharma investment. Discover how AI neuroscience platforms are driving precision psychiatry and psychedelic therapeutics.
Explore the FDA's Master Protocol guidance and how basket, umbrella, and platform trials can improve clinical trial efficiency, especially in oncology and biologics.
As precision medicine narrows patient cohorts to rare‑disease scales, deep learning models face a paradox of data scarcity and overfitting that threatens the future of clinical AI.
Operation TrialBlazer aims to reignite U.S. clinical development by accelerating trials, modernising FDA oversight, and strengthening pharmaceutical innovation.
Discover why genomic equity is essential for reliable AI-driven drug discovery, precision medicine, and building more representative pharmaceutical innovation.
The FDA's proposed drug manufacturing modernisation rule could accelerate distributed manufacturing, digital quality systems, and pharma supply chain resilience.
Discover how innovations in AAV vector manufacturing are improving scalability, quality, and commercial readiness for next-generation gene therapies.
We've mapped the competitive, regulatory, and commercial stakes of the top 11 clinical trials that have defined pharma strategy so far in 2026.
Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.